Skip to main
BVS

Bioventus (BVS) Stock Forecast & Price Target

Bioventus (BVS) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioventus Inc reported a quarterly revenue of $55.5 million from its surgical solutions segment, reflecting a 3.4% increase and a robust 10.3% growth after excluding the impact of divestitures, driven by effective commercial strategies and sales execution in its Exogen system. The pain treatments segment performed exceptionally well with $79.7 million in revenue, supported by anticipated future growth investments aimed at enhancing performance in peripheral nerve stimulation, platelet-rich plasma, and other areas. Management's guidance indicates a strong outlook for both segments, projecting low double-digit growth for surgical solutions in 2026 and significant adjusted EBITDA margin improvements anticipated between 2025 and 2030.

Bears say

Bioventus is expected to invest heavily in key growth areas during 2026 and 2027, which may lead to flat or slightly declining adjusted EBITDA margins compared to 2025. The company reported a significant decline of 26.0% in restorative therapies revenue, coupled with an overall 8.6% decline in international revenue, raising concerns about its growth trajectory. Additionally, the gross margin for the quarter was below expectations at 68.9%, further highlighting potential operational inefficiencies.

Bioventus (BVS) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioventus (BVS) Forecast

Analysts have given Bioventus (BVS) a Buy based on their latest research and market trends.

According to 3 analysts, Bioventus (BVS) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioventus (BVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.